PharmaCyte Biotech Inc (PMCB)

[BioNewton]

Nice little write-up here. No doubt it will misleadingly be called a pump but in the end is just a 3rd party news update. Not a PR so may have no bearing on the pps but I do think it simply explains a few of the questions that pop up here. Here are some below.

1.) Early studies have shown that the Cell-in-a-Box technology can be used to encapsulate a human cell line genetically engineered to produce, store, and secrete insulin, thereby representing a potential cure for Diabetes through a true bio-artificial pancreas.

Its a remarkable technology, and its closer to getting into an FDA clinical trial than ever.


2.) Orphan Drug status has already been awarded to PharmaCytes Pancreatic Cancer treatment, which gives the company 7 years of marketing exclusivity in the United States and could simplify and shorten the process. The company is moving towards completing the following steps to get into the pivotal human clinical trials:

3.) PharmaCyte (PMCB) represents a unique opportunity to make a little capital go a long way over time. This stock is not widely followed by the Biotech community at present, but as the company hits its milestones in the coming weeks and months, more and more investors in the sector will take notice of their progress.

4.) Owning a position in PharmaCyte (PMCB) is a bit like owning an option that never expires. The upside of the investment is magnified by the shear scope of the potential therapies - rarely do you find a low priced stock in the biotech sector that has a legitimate shot at becoming a treatment for cancer and a cure for diabetes.

5.) Something amazing happened in the late 1990's and the early part of the 21st Century. There were two studies done using a new technology for treating Pancreatic Cancer. At a clinic in Germany, 14 patients with Stage III and Stage IV Pancreatic Cancer were treated. The standard chemotherapy was used but it was activated in a new and revolutionary manner. Instead of just using the usual Chemotherapy in the blood stream, a technology allowed scientists to specially target the tumor with the usually toxic medicine with laser like accuracy right at the site of the tumor, and in turn, dramatically improved the outcome and lowered toxicity.